While immune checkpoint inhibitors (ICIs) have revolutionised the treatment of several cancers, they can also cause immune-related adverse events (IRAEs), including diarrhoea and colitis. Prompt recognition and treatment of IRAEs is crucial for managing symptoms and preventing life-threatening complications. This article discusses how a nurse-led cancer treatment unit diagnosed and treated immunotherapy-induced diarrhoea and colitis in an 80-year-old man with lung cancer receiving immunotherapy with the ICI pembrolizumab. It highlights the importance of using person-centred communication when interacting with patients; of educating patients regarding treatment-induced adverse events and when to contact the clinical team; of conducting systematic assessments and thorough investigations to determine the cause of symptoms; and of identifying patients’ psychological and social needs. More research is needed to establish whether patients who experience IRAEs should be re-exposed to immunotherapy.
Isabel Stewart (Wed,) studied this question.